By Route of Administration

Intravenous (Clinic/Infusion Center-Administered) Market Analysis

Cross-industry research covering Intravenous (Clinic/Infusion Center-Administered) across 1 market reportspanning Pharmaceuticals & Medical Devices — Ophthalmic Surgery.

1 Reports

1 Industries

Reports Covering Intravenous (Clinic/Infusion Center-Administered)

Oculoplastic Surgery Market to Reach USD 8.4 Billion by 2033 at 7.2% CAGR

Pharmaceuticals & Medical Devices — Ophthalmic Surgery·Market: USD 4.8 Billion (2025)·CAGR: 7.2%

Currently the dominant route for TED biologic therapy, billing under Medicare Part B as a physician-administered drug; this channel commands higher gross reimbursement but carries access barriers including infusion center scheduling and patient travel burden, which VRDN-003's subcutaneous program is explicitly designed to address (NCT06625411).

19%

Market Share

8.2%

Segment CAGR

Explore More Segments

Browse all market segments across our research coverage.

View all segments